Axi-cel, tisa-cel, and brexu-cel were found comparable to other cellular therapy experiences for patients with B-cell ...

CD19 and CD22 conjugated to deglycosylated ricin A chain (dgRTA) have been tested in patients with non-Hodgkin's lymphoma (NHL), but not in patients with pre-B ALL. Because of the encouraging ...

转座子工程化供体来源的抗 CD19.CD28.OX40.CD3ζ T 细胞（CAR CIK-CD19）治疗异基因造血干细胞移植（alloHSCT）后复发的 B 细胞前体急性淋巴细胞白血病（BCP-ALL）的研究。结果显示该疗法安全且能诱导缓解，为相关治疗提供新方向。 在癌症治疗领域，白血病一直是严重 ...

本期推荐：南方医科大学团队针对CAR-NK细胞治疗B细胞恶性肿瘤中持久性不足的难题，创新性地构建了IL-21共表达的CD19-CAR-NK细胞。研究发现，相较于传统IL-15修饰方案，CAR-21 NK细胞通过激活JAK-STAT信号通路和糖酵解代谢重编程，显著提升IFN-γ、TNF-α等效应因子分泌 ...

Treatment of B-cell cancers has been transformed by cluster of differentiation 19 (CD19)-targeting CAR T-cell therapies. Nevertheless, tumor CD19 antigen expression that is low or downregulated in ...

Inebilizumab-cdon (Uplizna; Amgen) was approved as the first and only treatment for immunoglobulin G4–related disease ...

Building on its autologous CD19 CAR-T cell therapy obe-cel, Autolus added a CD22 CAR to create AUTO1/22. The dual mechanism is intended to address a major cause of treatment failure. Thursday ...

The U.S. FDA has approved Autolus Therapeutics' Aucatzyl (obecabtagene autoleucel), a CD19-directed genetically modified autologous T cell immunotherapy, for adults with relapsed or refractory B ...

(NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS ® T-cell therapies to treat cancer and autoimmune ...